# TUDCA in High-Risk Lactating Mothers Identified by Early Postpartum Milk Hydrophobicity Index

> **NCT07517276** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Peking University First Hospital** · enrollment: 80 (estimated)

## Conditions studied

- Metabolic Dysfunction-Associated Steatotic Liver Disease Infant Development

## Interventions

- **DRUG:** tauroursodeoxycholic acid (TUDCA)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07517276
- **Lead sponsor:** Peking University First Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-02
- **Primary completion:** 2026-05-30
- **Final completion:** 2026-07-30
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2026-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07517276

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07517276, "TUDCA in High-Risk Lactating Mothers Identified by Early Postpartum Milk Hydrophobicity Index". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07517276. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*